Q-omics provides the consensus-scored BRICD5 profile across patient tissues and cancer cell-line models. BRICD5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BRICD5 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, BRICD5 RNA expression shows 17,673 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where BRICD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRICD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRICD5 survival associations across molecular data types. BRICD5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRICD5 RNA expression–survival associations across cancer types. High BRICD5 expression shows unfavorable associations in KIRC, ACC and COAD, but favorable associations in HNSC, BLCA and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BRICD5 RNA expression.
This table summarizes BRICD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for BRICD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRICD5 shows higher tumor expression in COAD, LIHC, BLCA, HNSC, UCEC and STAD. The COAD box plot shows higher BRICD5 RNA expression in tumor versus normal tissue (log2 FC = +0.970, t-test p < 0.001).
This table shows molecular features associated with BRICD5 in patient tissues and cancer cell lines. In patient samples, BRICD5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BRICD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
